BCHE and early-onset autosomal dominant Alzheimer disease: Currently, galanthamine, donepezil, and rivastigmine are the only cholinesterase inhibitor drugs approved by FDA for the clinical treatment of mild to moderate Alzheimer’s disease symptoms.